DK2151235T3 - Farmaceutisk formulering til behandling af den øvre fordøjelseskanal - Google Patents

Farmaceutisk formulering til behandling af den øvre fordøjelseskanal

Info

Publication number
DK2151235T3
DK2151235T3 DK08013091.7T DK08013091T DK2151235T3 DK 2151235 T3 DK2151235 T3 DK 2151235T3 DK 08013091 T DK08013091 T DK 08013091T DK 2151235 T3 DK2151235 T3 DK 2151235T3
Authority
DK
Denmark
Prior art keywords
treating
pharmaceutical formulation
digestive tract
upper digestive
antiinflammatory
Prior art date
Application number
DK08013091.7T
Other languages
Danish (da)
English (en)
Inventor
Markus Proels
Rudolf Wilhelm
Original Assignee
Falk Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39951664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2151235(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Falk Pharma Gmbh filed Critical Falk Pharma Gmbh
Application granted granted Critical
Publication of DK2151235T3 publication Critical patent/DK2151235T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DK08013091.7T 2008-07-21 2008-07-21 Farmaceutisk formulering til behandling af den øvre fordøjelseskanal DK2151235T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08013091A EP2151235B1 (de) 2008-07-21 2008-07-21 Pharmazeutische Formulierung zur Behandlung des oberen Verdauungstraktes

Publications (1)

Publication Number Publication Date
DK2151235T3 true DK2151235T3 (da) 2011-04-11

Family

ID=39951664

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08013091.7T DK2151235T3 (da) 2008-07-21 2008-07-21 Farmaceutisk formulering til behandling af den øvre fordøjelseskanal
DK09800023.5T DK2306988T3 (da) 2008-07-21 2009-07-02 Farmaceutisk formulering til behandling af den øvre fordøjelseskanal

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09800023.5T DK2306988T3 (da) 2008-07-21 2009-07-02 Farmaceutisk formulering til behandling af den øvre fordøjelseskanal

Country Status (23)

Country Link
US (2) US8580300B2 (enExample)
EP (2) EP2151235B1 (enExample)
JP (2) JP5616889B2 (enExample)
CN (1) CN102159196B (enExample)
AT (1) ATE498396T1 (enExample)
AU (1) AU2009273361B2 (enExample)
CA (1) CA2731312C (enExample)
CY (2) CY1111878T1 (enExample)
DE (1) DE502008002621D1 (enExample)
DK (2) DK2151235T3 (enExample)
EA (1) EA018465B1 (enExample)
ES (2) ES2358158T3 (enExample)
HR (2) HRP20130171T1 (enExample)
IL (1) IL210779A (enExample)
ME (2) ME01256B (enExample)
NZ (1) NZ590593A (enExample)
PL (2) PL2151235T3 (enExample)
PT (2) PT2151235E (enExample)
RS (2) RS51649B (enExample)
SI (2) SI2151235T1 (enExample)
UA (1) UA100759C2 (enExample)
WO (1) WO2010009961A1 (enExample)
ZA (1) ZA201100283B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1183014T3 (da) 1999-06-14 2004-02-09 Cosmo Spa Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP2151235B1 (de) * 2008-07-21 2011-02-16 Dr. Falk Pharma Gmbh Pharmazeutische Formulierung zur Behandlung des oberen Verdauungstraktes
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
PT3403654T (pt) 2009-10-01 2019-09-05 Adare Dev I L P Composições de corticosteroide administradas oralmente
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
EP2886108B2 (de) * 2013-12-23 2022-11-02 Dr. Falk Pharma Gmbh Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5639475A (en) * 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5807578A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807577A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
GB9611364D0 (en) * 1996-05-31 1996-08-07 Smithkline Beecham Plc Composition
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
JP3818789B2 (ja) * 1999-02-18 2006-09-06 三菱化学フーズ株式会社 易崩壊性錠剤
WO2003006629A1 (en) 2001-07-11 2003-01-23 Toshirou Sekine Culturing method and device for photosynthetic microbes
EP1432410A2 (en) * 2001-09-25 2004-06-30 Ranbaxy Laboratories, Ltd. Process for the preparation of fast dissolving effervescent dosage form
AU2002348301B2 (en) * 2001-11-20 2008-05-08 Dmi Biosciences, Inc. Methods and products for oral care
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060013873A1 (en) * 2004-07-16 2006-01-19 Chih-Chiang Yang Bioadhesive dosage form of steroids
US20070071817A1 (en) * 2005-09-26 2007-03-29 Phyzz, Inc. Effervescent oral care compositions and method of use
JP2009526619A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 質量減量を伴うコルチコステロイドの滅菌
PT2170348T (pt) * 2007-06-22 2016-11-02 Dompé Farm S P A Comprimidos efervescentes para utilização por via inalatória
PL2572705T3 (pl) * 2007-10-01 2018-01-31 Lesvi Laboratorios Sl Tabletki ulegające rozpadowi w jamie ustnej
EP2151235B1 (de) * 2008-07-21 2011-02-16 Dr. Falk Pharma Gmbh Pharmazeutische Formulierung zur Behandlung des oberen Verdauungstraktes
WO2010144865A2 (en) * 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders

Also Published As

Publication number Publication date
RS51649B (sr) 2011-10-31
US20140079646A1 (en) 2014-03-20
JP2011528679A (ja) 2011-11-24
DE502008002621D1 (de) 2011-03-31
AU2009273361B2 (en) 2014-03-20
EA201100229A1 (ru) 2011-08-30
PT2306988E (pt) 2013-02-15
IL210779A (en) 2015-07-30
CA2731312A1 (en) 2010-01-28
CN102159196A (zh) 2011-08-17
CA2731312C (en) 2016-05-10
UA100759C2 (uk) 2013-01-25
ATE498396T1 (de) 2011-03-15
HRP20110208T1 (hr) 2011-04-30
RS52662B (sr) 2013-06-28
JP5616889B2 (ja) 2014-10-29
PL2306988T3 (pl) 2013-04-30
EP2306988B1 (de) 2013-01-09
ES2399321T3 (es) 2013-03-27
JP2014221827A (ja) 2014-11-27
ME01494B (me) 2014-04-20
EP2151235B1 (de) 2011-02-16
EA018465B1 (ru) 2013-08-30
EP2151235A1 (de) 2010-02-10
ES2358158T3 (es) 2011-05-06
EP2306988A1 (de) 2011-04-13
PL2151235T3 (pl) 2011-05-31
ZA201100283B (en) 2011-10-26
SI2306988T1 (sl) 2013-03-29
CN102159196B (zh) 2013-05-08
SI2151235T1 (sl) 2011-04-29
HRP20130171T1 (hr) 2013-03-31
NZ590593A (en) 2012-07-27
IL210779A0 (en) 2011-03-31
US8580300B2 (en) 2013-11-12
WO2010009961A1 (de) 2010-01-28
ME01256B (me) 2013-06-20
PT2151235E (pt) 2011-03-21
AU2009273361A1 (en) 2010-01-28
HK1149907A1 (en) 2011-10-21
CY1111878T1 (el) 2015-11-04
JP6209495B2 (ja) 2017-10-04
DK2306988T3 (da) 2013-03-18
US20110123460A1 (en) 2011-05-26
CY1113719T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
DK2151235T3 (da) Farmaceutisk formulering til behandling af den øvre fordøjelseskanal
AR114143A2 (es) Formulaciones de comprimidos revestidos
EP2440210A4 (en) METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
IL255752B (en) Compounds, pharmaceutical compositions comprising the same and uses thereof for treating cardiovasclar disease, an inflammatory disease or cancer
DK2010190T3 (da) Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer
CL2008000219A1 (es) Composicion farmaceutica de liberacion modificada que comprende a uno o mas ingredientes farmaceuticamente activos, con solubilidad dependiente del ph, un polimero controlador de la liberacion, agentes facilitadores de la gelificacion; procedimiento
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2009014650A3 (en) Recombinant vibrio cholerae exotoxins
EP2413930A4 (en) ORAL FORMULATION OF ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS BASED ON DIPHENYLSULFONAMIDE TO TREAT HIGH BLOOD PRESSURE AND DIABETIC NEPHROPATHY
HRP20190306T1 (hr) Niže jačine doze formulacija imikvimoda i kratki režimi doziranja kod liječenja aktinične keratoze
DK2491942T3 (da) Anvendelse af cellepermeable peptidinhibitorer af JNK-signaltransduktionsvejen til behandling af forskellige kardiovaskulære sygdomme.
IN2012DN01435A (enExample)
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
WO2009040666A3 (en) Treatment of graft-versus-host disease
FR2953142B1 (fr) Appareil de delivrance regulee d'un gaz,notamment appareil d'assistance respiratoire
NO20083836L (no) N-hydroksyakrylamidforbindelser
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
WO2011072069A3 (en) Gastric retentive pharmaceutical compositions for extended release of polypeptides
DK2022504T3 (da) Salve til behandling af hæmorider
EP2508206A4 (en) FILM COATING AGENT FOR A SOLID PREPARATE AND SOLID PREPARATION THEREFOR
CL2007003875A1 (es) Compuestos derivados de amidas del acido 3-amino tetrahidrofurano-3-carboxilico; procedimiento de preparacion de dichos compuestos.
DE502008002255D1 (de) Arzneimittel enthaltend Fraumenmantel zur Behandlung von Endometritis, Vaginitis
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
FR2910081B1 (fr) Appareil de delivrance regulee d'un gaz,notamment appareil d'assistance respiratoire
DK1979321T3 (da) Nye pyridinylaminoalkylen- og pyridinyloxyalkylen-cyclopropanaminer, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende dissse